Surgery Policy Improvement Research and Education Center (S-SPIRE), Stanford University School of Medicine, 300 Pasteur Drive H3642, Stanford, CA 94305, USA; Department of Surgery, Stanford University, School of Medicine, 300 Pasteur Drive H3642, Stanford, CA 94305, USA.
Department of Surgery, Stanford University, School of Medicine, 300 Pasteur Drive H3642, Stanford, CA 94305, USA.
Surg Oncol Clin N Am. 2023 Apr;32(2):233-250. doi: 10.1016/j.soc.2022.10.002.
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted therapies for MTC, including the selective RET inhibitors selpercatinib and pralsetinib, have led to changes in the management of patients with locally advanced, metastatic, or recurrent MTC. In this article, we review updates on the evaluation and management of patients with MTC, focusing on new and emerging therapies that are likely to improve patient outcomes.
甲状腺髓样癌（MTC）是一种罕见的神经内分泌肿瘤，可为散发或遗传性，常与 RET（转染过程中重排）癌基因突变相关。MTC 的主要治疗方法是手术切除所有可疑疾病，但 MTC 的靶向治疗方法最近取得了进展，包括选择性 RET 抑制剂塞尔帕替尼和普拉替尼，这导致了局部晚期、转移性或复发性 MTC 患者的治疗管理发生了变化。本文综述了 MTC 患者评估和管理的最新进展，重点关注可能改善患者预后的新出现的治疗方法。
